Pulmonary Arterial Hypertension (PAH) is still a devastating illness with substantial morbidity and death outcomes. Taking into account that the disease advances quickly for many patients, and is commonly associated with severe clinical symptoms, new treatment options are still r [....]
» Read More
Title : Pharmacological advancement in pulmonary arterial hypertension treatment - Contribution of treprostinil dry-powder formulation
Miroslav Radenkovic, University of Belgrade, Serbia
Pulmonary Arterial Hypertension (PAH) is still a devastating illness with substantial morbidity and death outcomes. Taking into account that the disease advances quickly for many patients, and is commonly associated with severe clinical symptoms, new treatment options are still r [....] » Read More